Wearable Injectors Companies

The global wearable injectors market is projected to reach USD 18.91 billion by 2030 from USD 11.33 billion in 2025, at a CAGR of 10.8% during the forecast period.

The wearable injectors market is primarily driven by several key factors, including the increasing preference for home healthcare and self-administration, a rise in research and development activities, and strategic partnerships. Additionally, artificial intelligence is being increasingly used in diabetes management devices.

Globally, the prevalence of chronic illnesses such as diabetes, cancer, and cardiovascular diseases has significantly increased. This trend, combined with an expanding elderly population, is propelling the growth of the wearable injectors market. Furthermore, the rising incidence of chronic conditions has escalated the demand for home care treatments, which are essential for improving patient compliance and health outcomes.

To know about the assumptions considered for the study download the pdf brochure

This shift towards home healthcare highlights the need for innovative wearable injectors that can cater to a diverse patient population while ensuring effective therapeutic management. Emerging markets, such as India, Brazil, and Southeast Asia, present attractive opportunities for growth in this sector. However, challenges like the high cost of wearable injectors and stringent regulatory requirements may restrain market expansion to some extent.

The prominent players offering wearable injector devices are Medtronic (Ireland), BD (US), West Pharmaceutical Services, Inc. (US), Gerresheimer AG (Germany), and Insulet Corporation (US). Prominent players offering wearable injector formulations include Amgen Inc. (US), AbbVie Inc. (US), United Therapeutics Corporation (US), Apellis Pharmaceuticals, Inc. (US), and Supernus Pharmaceuticals, Inc. (US).

These companies have adopted various growth strategies, including new product launches, strategic partnerships, and expansions into emerging markets, to increase their market shares and diversify their portfolios.

• In April 2025, Medtronic received US FDA approval for the Simplera Sync sensor, enhancing the MiniMed 780G system's flexibility with Meal Detection technology and the Guardian 4 sensor.
• In February 2023, Insulet Corporation acquired assets related to Bigfoot's automated insulin delivery technologies, including patents for pump usage in AID therapy. This integration will advance closed-loop monitoring and treatment systems, improving diabetes care.

Medtronic (Ireland) is a medical technology company that provides innovative solutions for over 30 chronic diseases, including cardiovascular and diabetes conditions. It operates through four segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, offering wearable injectors in the latter. The company is recognized for its innovation and has a significant presence in the US, Europe, and Japan, with manufacturing and research facilities in multiple countries. The company has pursued both organic growth and strategic acquisitions. In April 2025, it received FDA approval for the Simplera Sync sensor for use with the MiniMed 780G system, enhancing insulin delivery flexibility. In 2023, Medtronic acquired EOFlow Co. Ltd., which manufactures the EOPatch, a tubeless insulin delivery device, furthering its capabilities to assist individuals with diabetes.

AbbVie Inc. (US) is a leading biopharmaceutical company focused on research and innovation in areas such as oncology, autoimmune diseases, virology, and neurology. The company offers drugs across various therapeutic segments, including its wearable injector Skyrizi for immunology. Operating in over 70 countries with 22 R&D facilities, AbbVie announced in 2024 that the FDA approved VYALEV as the first subcutaneous 24-hour infusion therapy for motor fluctuations in advanced Parkinson's disease. Additionally, AbbVie expanded its presence in Germany with a new research center, LUnA, investing approximately USD 172 million to create its second-largest R&D location globally.

Market Ranking:

The wearable injectors market consists of device manufacturers and formulation providers, with top companies such as Insulet Corporation (US), Medtronic (Ireland), Tandem Diabetes Care, Inc. (US), BD (US), and West Pharmaceutical Services, Inc. (US).

Insulet is known for its OmniPod system and pump-based automated insulin delivery technologies. Medtronic focuses on miniaturized smart wearable systems for diabetes management. Tandem integrates digital health, remote monitoring, and IoT into its wearable injectors. BD specializes in user-friendly, large-volume wearable injectors with advanced safety features. West Pharmaceutical is recognized for its proprietary platforms and collaborations for subcutaneous biologic delivery.

The top five companies offering wearable injector formulations are Amgen Inc. (US), AbbVie Inc. (US), United Therapeutics Corporation (US), Apellis Pharmaceuticals (US), and Supernus Pharmaceuticals (US). These firms focus on biologics and specialty drugs for subcutaneous self-administration via wearable devices.

Amgen leads with its Neulasta Onpro kit, while AbbVie offers SKYRIZI for moderate to severe plaque psoriasis and emphasizes drug-device combinations for patient adherence. United Therapeutics develops wearable systems like Remodulin for pulmonary arterial hypertension. Apellis and Supernus Pharmaceuticals are advancing long-acting and neurology-focused therapies compatible with wearable injectors to improve chronic treatment outcomes.

Related Reports:

Wearable Injectors Market by Product (On-body, Off-body), Technology (Spring, Motor Driven, Rotary Pump), Usage (Disposable, Reusable), Delivery Method (Bolus, Programmed Infusion), Therapeutic Application (Diabetes, Oncology), End User - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com